Department of Dermatology, Skin Cancer Unit, and National Centre for Rare Skin Diseases, CHU St-André, Bordeaux, France.
Eur J Cancer. 2010 Dec;46(18):3316-22. doi: 10.1016/j.ejca.2010.06.008. Epub 2010 Jul 6.
In the SU.VI.MAX study, antioxidant supplementation for 7.5 years was found to increase skin cancer risk in women but not in men.
To investigate the potential residual or delayed effect of antioxidant supplementation on skin cancer incidence after a 5-year post-intervention follow-up.
DESIGN, SETTING AND PARTICIPANTS: Assessment of skin cancer including melanoma and non-melanoma during the post-intervention follow-up (September 2002-August 2007). The SU.VI.MAX study was a double-blind, placebo-controlled, randomised trial, in which 12,741 French adults (7713 women aged 35-60 years and 5028 men aged 45-60 years) received daily a placebo or a combination of ascorbic acid (120 mg), vitamin E (30 mg), β-carotene (6 mg), selenium (100 μg) and zinc (20mg), from inclusion in 1994 to September 2002.
Total skin cancer incidence, including melanoma, squamous cell carcinoma and basal cell carcinoma.
During the post-intervention period, 10 melanomas appeared in women and 9 in men (26 and 18, respectively, for the total period of supplementation+post-supplementation). Six squamous cell carcinomas were found in women and 15 in men (10 and 25, respectively, for the total period). Finally, 40 basal cell carcinomas appeared in women and 36 in men (98 and 94, respectively, for the total period). Regarding potential residual or delayed effects of supplementation in women, no increased risk of melanoma was observed during the post-intervention follow-up period. No delayed effects, either on melanoma or non-melanoma skin cancers, were observed for either gender.
The risk of skin cancers associated with antioxidant intake declines following interruption of supplementation. This supports a causative role for antioxidants in the evolution of skin cancers.
在 SU.VI.MAX 研究中,抗氧化剂补充剂的使用 7.5 年后增加了女性的皮肤癌风险,但对男性没有影响。
研究在干预后 5 年的随访中,抗氧化剂补充对皮肤癌发病率的潜在残留或延迟影响。
设计、地点和参与者:在干预后随访期间(2002 年 9 月至 2007 年 8 月)评估皮肤癌(包括黑色素瘤和非黑色素瘤)。SU.VI.MAX 研究是一项双盲、安慰剂对照、随机试验,共有 12741 名法国成年人(7713 名年龄在 35-60 岁的女性和 5028 名年龄在 45-60 岁的男性)从 1994 年纳入研究至 2002 年 9 月,每日接受安慰剂或维生素 C(120mg)、维生素 E(30mg)、β-胡萝卜素(6mg)、硒(100μg)和锌(20mg)的组合补充剂。
皮肤癌总发病率,包括黑色素瘤、鳞状细胞癌和基底细胞癌。
在干预后期间,女性中出现了 10 例黑色素瘤,男性中出现了 9 例(总补充+补充后期间分别为 26 例和 18 例)。女性中发现了 6 例鳞状细胞癌,男性中发现了 15 例(总期间分别为 10 例和 25 例)。最后,女性中出现了 40 例基底细胞癌,男性中出现了 36 例(总期间分别为 98 例和 94 例)。关于女性补充剂的潜在残留或延迟作用,在干预后随访期间未观察到黑色素瘤风险增加。对于两性,均未观察到黑色素瘤或非黑色素瘤皮肤癌的延迟作用。
抗氧化剂摄入与皮肤癌风险相关,中断补充后风险下降。这支持了抗氧化剂在皮肤癌演变中的因果作用。